A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs, and other critical areas.
|Articles|May 25, 2011
Oncology Nurse Edition Editorial and Publishing Staff April 2011
Advertisement
EDITORIAL AND PUBLISHING STAFF
Cindy FlaumVP, Clinical Publishing
Rachel WarrenEditorial Director
Anne LandryExecutive Editor
Nancy BittekerDirector, Design & Digital Production
Meg StrizverProduction Manager
Amy Birnbach
Group Publisher, Oncology
Sarah MifsudDigital Sales
William Markowitz, RPhPublishing Director
Advertisement
Related to this article
Data from the phase 3 HARMONi-GI1 trial support first-line ivonescimab plus chemotherapy as a new standard of care in advanced biliary tract cancer.
Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.
Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma in CLARITY-Gastric01.
Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.
Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.
Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Divarasib Improves Survival vs Sotorasib or Adagrasib in KRAS G12C+ NSCLC
2
Ivonescimab Combo Improves Survival in Advanced Biliary Tract Cancer
3
Osimertinib/Savolitinib Improves Survival in MET-Altered EGFR-Mutant NSCLC
4
Sonesitatug Vedotin Improves OS in Pretreated CLDN18.2+ Gastroesophageal Cancer
5